RT Journal Article
T1 Homocysteine levels, genetic background, and cognitive impairment in Parkinson's disease.
A1 Periñán, María Teresa
A1 Macías-García, Daniel
A1 Jesús, Silvia
A1 Martín-Rodríguez, Juan Francisco
A1 Muñoz-Delgado, Laura
A1 Jimenez-Jaraba, Maria Valle
A1 Buiza-Rueda, Dolores
A1 Bonilla-Toribio, Marta
A1 Adarmes-Gómez, Astrid Daniela
A1 Gómez-Garre, Pilar
A1 Mir, Pablo
K1 Cognitive impairment
K1 Homocysteine
K1 MTHFR
K1 Meta-analysis
K1 Parkinson’s disease
AB Hyperhomocysteinemia is considered an independent risk factor for cognitive impairment. To study the correlation between homocysteine levels and cognitive impairment in patients with PD. We conducted a case-control study that included 246 patients with PD, of whom 32 were cognitively impaired. The levels of homocysteine, folate, and vitamin B12 were measured in peripheral blood. Multivariate logistic regression analysis was applied to determine differences in homocysteine levels between PD patients with and without cognitive impairment. A meta-analysis was performed to clarify the role of Hcy levels in PD with cognitive decline. Five polymorphisms in genes involved in Hcy metabolism, including MTHFR rs1801133 and rs1801131, COMT rs4680, MTRR rs1801394, and TCN2 rs1801198, were genotyped. Our case-control study showed that homocysteine levels were associated with cognitive impairment in PD after adjusting for possible confounding factors such as levodopa equivalent daily dose. The results of our meta-analysis further supported the positive association between homocysteine levels and cognition in PD. We found that the MTHFR rs1801133 TT genotype led to higher homocysteine levels in PD patients, whereas the MTHFR rs1801131 CC genotype resulted in higher folate levels. However, the polymorphisms studied were not associated with cognitive impairment in PD. Increased homocysteine levels were a risk factor for cognitive decline in PD. However, no association was found between polymorphisms in genes involved in homocysteine metabolism and cognitive impairment in PD. Large-scale studies of ethnically diverse populations are required to definitively assess the relationship between MTHFR and cognitive impairment in PD.
YR 2022
FD 2022-09-28
LK http://hdl.handle.net/10668/20030
UL http://hdl.handle.net/10668/20030
LA en
DS RISalud
RD Apr 9, 2025